Bromoenol lactone, an inhibitor of Group V1A calcium-independent phospholipase A2 inhibits antigen-stimulated mast cell exocytosis without blocking Ca2+ influx.
Calcium-independent phospholipase A2 (iPLA2beta) has recently been suggested to regulate Ca2+ entry by activating store-operated Ca2+ channels. These studies have been conducted in mast cells using thapsigargin to deplete intracellular stores. In RBL 2H3 and bone marrow-derived mast cells (BMMCs), Ca2+ entry is critical for exocytosis and therefore we have examined whether the proposed mechanism would be relevant when a physiological stimulus is applied to these cells. Using an iPLA2beta antibody, we demonstrate that the 84kDa iPLA2beta is expressed in these mast cells. As bromoenol lactone (BEL) is a suicide-based irreversible inhibitor of iPLA2beta it was used to probe this potential mechanism. We observe inhibition of exocytosis stimulated either with antigen or with thapsigargin. However, BEL also inhibits exocytosis when stimulated using a Ca2+ ionophore A23187, which passively transports Ca2+ down a concentration gradient and also in permeabilised mast cells where Ca2+ entry is no longer relevant. Moreover, BEL has only a minor effect on antigen- or thapsigargin-stimulated Ca2+ signalling, both the release from internal stores and sustained elevation due to Ca2+ influx. These results cast doubt on the proposed mechanism involving iPLA2beta required for Ca2+ entry. Although inhibition of exocytosis by BEL could imply a requirement for iPLA2beta activation for exocytosis, an alternative explanation is that BEL inactivates other target proteins required for exocytosis.
Fensome-Green
Amanda
A
Department of Physiology, University College London, Rockefeller Building, 21 University Street, London WC1E 6JJ, United Kingdom.
Stannard
Naina
N
Li
Michelle
M
Bolsover
Stephen
S
Cockcroft
Shamshad
S
D000818:Animals; D000941:Antigens / Q000494:pharmacology; D016718:Arachidonic Acid / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D045744:Cell Line, Tumor; D004347:Drug Interactions; D005089:Exocytosis; D054522:Group VI Phospholipases A2; D007476:Ionophores / Q000494:pharmacology; D008244:Lysophosphatidylcholines / Q000494:pharmacology; D008407:Mast Cells / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009281:Naphthalenes / Q000494:pharmacology*; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D011753:Pyrones / Q000494:pharmacology*; D051381:Rats; D019284:Thapsigargin / Q000494:pharmacology
D000941:Antigens; D007476:Ionophores; D008244:Lysophosphatidylcholines; D009281:Naphthalenes; D011753:Pyrones; D016718:Arachidonic Acid; D019284:Thapsigargin; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; D010741:Phospholipases A; D054522:Group VI Phospholipases A2; D054467:Phospholipases A2; D002118:Calcium